About LIM homeobox transcription factor 1-beta
LIM homeobox transcription factor 1-beta (LMX1B) is a protein
from Homo sapiens identified by UniProt accession
O60663, 402 residues long.
MolForge cross-references it against 0 known binders and
313 disease associations.
Target properties
| Protein name | LIM homeobox transcription factor 1-beta |
| UniProt accession | O60663 |
| Gene | LMX1B |
| Organism | Homo sapiens |
| Length | 402 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (313)
Diseases linked to this target (Open Targets).
- nail-patella syndrome · score 0.85
- nail-patella-like renal disease · score 0.68
- focal segmental glomerulosclerosis · score 0.61
- glaucoma · score 0.54
- body mass index · score 0.53
- open-angle glaucoma · score 0.53
- intraocular pressure measurement · score 0.52
- lean body mass · score 0.50
- refractive error measurement · score 0.50
- body fat percentage · score 0.49
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60663-F1 | alphafold | PREDICTED | 69.77 | — |
Amino-acid sequence (402 residues)
MDIATGPESL ERCFPRGQTD CAKMLDGIKM EEHALRPGPA TLGVLLGSDC PHPAVCEGCQ RPISDRFLMR VNESSWHEEC LQCAACQQAL TTSCYFRDRK LYCKQDYQQL FAAKCSGCME KIAPTEFVMR ALECVYHLGC FCCCVCERQL RKGDEFVLKE GQLLCKGDYE KEKDLLSSVS PDESDSVKSE DEDGDMKPAK GQGSQSKGSG DDGKDPRRPK RPRTILTTQQ RRAFKASFEV SSKPCRKVRE TLAAETGLSV RVVQVWFQNQ RAKMKKLARR HQQQQEQQNS QRLGQEVLSS RMEGMMASYT PLAPPQQQIV AMEQSPYGSS DPFQQGLTPP QMPGDHMNPY GNDSIFHDID SDTSLTSLSD CFLGSSDVGS LQARVGNPID RLYSMQSSYF AS
Explore LIM homeobox transcription factor 1-beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets